Literature DB >> 31002890

Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells.

Guoli Wu1, Mimi Niu1, Jian Qin2, Yafei Wang1, Jing Tian3.   

Abstract

Previous studies report the upregulation of the secretory Rab27B small GTPase in human breast cancer, which could promote invasive growth and metastasis in estrogen receptor (ER)-positive breast cancer cells. However, there is limited evidence for its role in ER-negative breast cancer, along with the signaling pathways. Consistent with previous studies, we here confirmed that Rab27B is upregulated in breast tumor tissue in comparison with normal breast tissue. In addition, in ER-negative breast cancer cell line MDA-MB-231, when the levels of Rab27B expression were further elevated by transduction with recombinant lentivirus vector, migration and invasion assays demonstrated that cell migration and invasion was significantly stimulated. Moreover, Rab27B overexpression increased levels of β-catenin, followed by upregulation of vascular endothelial growth factor (VEGF). Our findings reveal a key function for the Rab27B-mediated modulation of β-catenin and VEGF in ER-negative breast cancer cell metastasis. Notably, the suppressed expression of Rab27B, β-catenin and VEGF was found in calycosin-treated MDA-MB-231 cells, accompanied with decreased invasive and migratory potential of these cells. What's more, these inhibitory effects of calycosin were all attenuated by Rab27B overexpression. The results demonstrated that calycosin-induced inhibition of migration and invasion in ER-negative breast cancer cells may be associated with the inactivation of Rab27B-dependent signaling, and suggest that antagonism of this pathway by calycosin may offer alternative therapeutic strategy for the aggressive breast cancer.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Breast cancer; Calycosin; Invasion; Migration; Phytoestrogens; Rab27B

Mesh:

Substances:

Year:  2019        PMID: 31002890     DOI: 10.1016/j.gene.2019.04.005

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

Review 1.  Pharmaceutical Values of Calycosin: One Type of Flavonoid Isolated from Astragalus.

Authors:  Guowei Gong; Yuzhong Zheng; Yang Yang; Yixuan Sui; Zhen Wen
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-06       Impact factor: 2.629

2.  Calycosin induces apoptosis via p38‑MAPK pathway‑mediated activation of the mitochondrial apoptotic pathway in human osteosarcoma 143B cells.

Authors:  Wei Tian; Zhi-Wei Wang; Bao-Ming Yuan; Yong-Ge Bao
Journal:  Mol Med Rep       Date:  2020-09-01       Impact factor: 2.952

3.  RAB27B inhibits proliferation and promotes apoptosis of leukemic cells via 3-Hydroxy butyrate dehydrogenase 2 (BDH2).

Authors:  Can Meng; Li Huang; Xiangjun Fu; Bin Wu; Lie Lin
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

4.  Extracts of Knoxia roxburghii (Spreng.) M. A. Rau Induce Apoptosis in Human MCF-7 Breast Cancer Cells via Mitochondrial Pathways.

Authors:  Xiao-Jiao Chen; Xin-Ying Pu; Xue-Mei Pu; Xue Li; Zhi-Bo Liu; Mi-Jia Mei; Xin-Ge Wang; Fan Zhang; Bin Qiu; Jie Yu
Journal:  Molecules       Date:  2022-09-29       Impact factor: 4.927

5.  Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF/TGF-β1.

Authors:  Zhenxia Zhang; Min Lin; Junli Wang; Fenglian Yang; Peikui Yang; Yaqun Liu; Zikai Chen; Yuzhong Zheng
Journal:  Aging (Albany NY)       Date:  2021-06-07       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.